Inscripta Stock
HealthTechLooking to sell Inscripta stock or options?
Inscripta has developed a gene-editing technology that provides scalable digital genome engineering with straightforward simplicity. Their technology creates affordable libraries of thousands of custom-made protein, pathway, or genome variants, each having specific and traceable mutations. This allows researchers to design, engineer, evaluate, and monitor results, making Inscripta's technology an essential tool in their field.
GoldenArc, Venture Partners at CU Boulder, Vertical Venture Partners, Foresite Capital, iGlobe Partners, Spruceview Capital Partners, OMX Ventures, D1 Capital Partners, T. Rowe Price Group, Morgan Stanley, Fidelity Management & Research Company, Oak HC/FT, Korys Investments, Venrock, ND Capital, Spruce Capital Partners, Phoenix International Investments, Durable Capital Partners, Counterpoint Global, JS Capital Management, Jonathan Feldstein, Paladin Capital Group.